Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2022 | 393 | 3.940 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2019 | 45 | 1.530 |
Why?
|
| Hematologic Diseases | 3 | 2017 | 78 | 1.170 |
Why?
|
| Immunotherapy | 2 | 2020 | 648 | 0.990 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 879 | 0.960 |
Why?
|
| Central Nervous System Diseases | 1 | 2022 | 52 | 0.810 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2022 | 84 | 0.770 |
Why?
|
| Ploidies | 1 | 2019 | 41 | 0.670 |
Why?
|
| Child | 16 | 2022 | 7039 | 0.630 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 190 | 0.620 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 64 | 0.560 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 261 | 0.530 |
Why?
|
| Adolescent | 18 | 2022 | 9080 | 0.510 |
Why?
|
| Immune System Diseases | 1 | 2015 | 26 | 0.510 |
Why?
|
| Burkitt Lymphoma | 1 | 2014 | 32 | 0.470 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2014 | 96 | 0.450 |
Why?
|
| Oxides | 2 | 2010 | 43 | 0.450 |
Why?
|
| Arsenicals | 2 | 2010 | 48 | 0.440 |
Why?
|
| Young Adult | 16 | 2021 | 6117 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2022 | 2508 | 0.420 |
Why?
|
| Folic Acid | 1 | 2011 | 61 | 0.390 |
Why?
|
| Carnitine | 2 | 2021 | 15 | 0.360 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2010 | 41 | 0.360 |
Why?
|
| Asparaginase | 2 | 2021 | 35 | 0.360 |
Why?
|
| Child, Preschool | 8 | 2019 | 3652 | 0.360 |
Why?
|
| Humans | 33 | 2022 | 87555 | 0.350 |
Why?
|
| Chemical and Drug Induced Liver Injury | 2 | 2021 | 68 | 0.340 |
Why?
|
| Communicable Diseases | 1 | 2010 | 63 | 0.340 |
Why?
|
| Injections, Spinal | 2 | 2022 | 44 | 0.340 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 192 | 0.330 |
Why?
|
| Antineoplastic Agents | 5 | 2021 | 2384 | 0.320 |
Why?
|
| Infant | 5 | 2019 | 3098 | 0.310 |
Why?
|
| Glucocorticoids | 1 | 2010 | 355 | 0.310 |
Why?
|
| Biomarkers, Tumor | 3 | 2021 | 1505 | 0.300 |
Why?
|
| Polyethylene Glycols | 2 | 2021 | 365 | 0.300 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 824 | 0.300 |
Why?
|
| Neoplasms | 3 | 2020 | 2970 | 0.290 |
Why?
|
| Remission Induction | 5 | 2019 | 730 | 0.280 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 266 | 0.230 |
Why?
|
| Male | 18 | 2021 | 41502 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 1343 | 0.220 |
Why?
|
| Prognosis | 4 | 2020 | 3708 | 0.220 |
Why?
|
| Female | 18 | 2021 | 45191 | 0.220 |
Why?
|
| Leukemia, B-Cell | 1 | 2022 | 23 | 0.210 |
Why?
|
| Etoposide | 2 | 2019 | 197 | 0.200 |
Why?
|
| Methotrexate | 1 | 2022 | 250 | 0.200 |
Why?
|
| Cytogenetic Analysis | 2 | 2019 | 71 | 0.190 |
Why?
|
| Retrospective Studies | 5 | 2022 | 8713 | 0.190 |
Why?
|
| Survivors | 2 | 2020 | 233 | 0.190 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 170 | 0.180 |
Why?
|
| Postoperative Complications | 1 | 2010 | 2236 | 0.170 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 334 | 0.170 |
Why?
|
| Infant, Newborn | 3 | 2019 | 2425 | 0.170 |
Why?
|
| Anthracyclines | 1 | 2019 | 37 | 0.170 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2019 | 776 | 0.170 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 1208 | 0.170 |
Why?
|
| Leukemia | 1 | 2021 | 321 | 0.160 |
Why?
|
| Recurrence | 1 | 2022 | 1162 | 0.160 |
Why?
|
| Cancer Survivors | 1 | 2020 | 89 | 0.160 |
Why?
|
| Hyperbilirubinemia | 1 | 2018 | 20 | 0.160 |
Why?
|
| Adult | 12 | 2021 | 26018 | 0.160 |
Why?
|
| Risk Factors | 3 | 2020 | 5373 | 0.150 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 47 | 0.150 |
Why?
|
| Salvage Therapy | 1 | 2018 | 234 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2018 | 8054 | 0.150 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 144 | 0.140 |
Why?
|
| Prevalence | 2 | 2018 | 1246 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2020 | 942 | 0.140 |
Why?
|
| Chemotherapy-Induced Febrile Neutropenia | 1 | 2016 | 6 | 0.140 |
Why?
|
| Blood Culture | 1 | 2016 | 11 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 179 | 0.140 |
Why?
|
| Escherichia coli Infections | 1 | 2016 | 35 | 0.130 |
Why?
|
| Bone Marrow Examination | 1 | 2015 | 47 | 0.130 |
Why?
|
| Radiotherapy | 1 | 2017 | 331 | 0.130 |
Why?
|
| Philadelphia Chromosome | 1 | 2015 | 38 | 0.130 |
Why?
|
| Imatinib Mesylate | 1 | 2015 | 126 | 0.130 |
Why?
|
| Bacteremia | 1 | 2016 | 102 | 0.130 |
Why?
|
| Survival Rate | 4 | 2021 | 1870 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 608 | 0.130 |
Why?
|
| Prednisone | 2 | 2017 | 258 | 0.120 |
Why?
|
| Guideline Adherence | 1 | 2016 | 225 | 0.120 |
Why?
|
| U937 Cells | 2 | 2010 | 32 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 471 | 0.110 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 389 | 0.110 |
Why?
|
| Escherichia coli | 1 | 2016 | 601 | 0.110 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 942 | 0.110 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2014 | 304 | 0.110 |
Why?
|
| Leukemia, T-Cell | 1 | 2012 | 17 | 0.110 |
Why?
|
| Stress, Psychological | 1 | 2016 | 320 | 0.110 |
Why?
|
| Pediatrics | 1 | 2017 | 348 | 0.110 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2014 | 383 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2012 | 52 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2012 | 102 | 0.100 |
Why?
|
| Transplantation, Homologous | 2 | 2012 | 994 | 0.100 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 54 | 0.100 |
Why?
|
| Dithiothreitol | 1 | 2010 | 25 | 0.090 |
Why?
|
| Biomarkers | 2 | 2022 | 1733 | 0.090 |
Why?
|
| Acetylcysteine | 1 | 2010 | 69 | 0.090 |
Why?
|
| Tretinoin | 1 | 2010 | 127 | 0.090 |
Why?
|
| Quality of Life | 1 | 2017 | 1631 | 0.090 |
Why?
|
| Area Under Curve | 1 | 2010 | 333 | 0.090 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2022 | 107 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2010 | 211 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2010 | 172 | 0.080 |
Why?
|
| Autophagy | 1 | 2010 | 152 | 0.080 |
Why?
|
| Enzyme Activation | 1 | 2010 | 694 | 0.080 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 900 | 0.080 |
Why?
|
| Dexamethasone | 1 | 2010 | 337 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 554 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2010 | 297 | 0.080 |
Why?
|
| Age Factors | 1 | 2012 | 1848 | 0.080 |
Why?
|
| Transplantation Conditioning | 1 | 2010 | 371 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2010 | 357 | 0.080 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 852 | 0.080 |
Why?
|
| ROC Curve | 1 | 2010 | 768 | 0.080 |
Why?
|
| Phosphorylation | 1 | 2010 | 1121 | 0.070 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 482 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 148 | 0.070 |
Why?
|
| Sex Factors | 1 | 2010 | 1055 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1687 | 0.060 |
Why?
|
| Cell Line, Tumor | 1 | 2010 | 2500 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2010 | 1365 | 0.050 |
Why?
|
| Mucin-4 | 1 | 2022 | 7 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2021 | 4232 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2016 | 2061 | 0.050 |
Why?
|
| United States | 3 | 2021 | 6769 | 0.050 |
Why?
|
| Base Sequence | 2 | 2016 | 2331 | 0.050 |
Why?
|
| Pediatric Obesity | 1 | 2021 | 23 | 0.050 |
Why?
|
| Acute Disease | 1 | 2022 | 832 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2021 | 766 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 278 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 93 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1535 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2022 | 1779 | 0.040 |
Why?
|
| Vincristine | 1 | 2017 | 112 | 0.040 |
Why?
|
| Vinblastine | 1 | 2017 | 108 | 0.040 |
Why?
|
| Bleomycin | 1 | 2017 | 100 | 0.040 |
Why?
|
| Chromosome Breakpoints | 1 | 2016 | 15 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2017 | 102 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 300 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2017 | 297 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2017 | 156 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 1473 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1031 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 185 | 0.030 |
Why?
|
| Oncologists | 1 | 2016 | 36 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 1695 | 0.030 |
Why?
|
| Marital Status | 1 | 2016 | 41 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2018 | 702 | 0.030 |
Why?
|
| Educational Status | 1 | 2016 | 192 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2016 | 223 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2016 | 331 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2791 | 0.030 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2014 | 130 | 0.030 |
Why?
|
| Anxiety | 1 | 2016 | 300 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2016 | 855 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 3640 | 0.030 |
Why?
|
| Liver | 1 | 2018 | 1235 | 0.030 |
Why?
|
| Genes, myc | 1 | 2012 | 39 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2012 | 49 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 85 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 1962 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 492 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 74 | 0.030 |
Why?
|
| World Health Organization | 1 | 2012 | 103 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 1569 | 0.020 |
Why?
|
| Immunophenotyping | 1 | 2012 | 214 | 0.020 |
Why?
|
| Time Factors | 1 | 2020 | 5262 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 257 | 0.020 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2010 | 6 | 0.020 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2010 | 12 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 1674 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 1818 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2010 | 195 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 200 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 182 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2010 | 1967 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2010 | 1210 | 0.010 |
Why?
|
| Aged | 1 | 2021 | 18644 | 0.010 |
Why?
|
| Mice | 1 | 2010 | 11586 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 26951 | 0.010 |
Why?
|